Detalhe da pesquisa
1.
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
N Engl J Med;
388(19): 1739-1754, 2023 May 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37163621
2.
High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations.
Blood;
142(5): 446-459, 2023 08 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37172204
3.
Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol;
24(12): 1423-1433, 2023 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37944541
4.
Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma.
Blood;
137(5): 637-645, 2021 02 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32870269
5.
Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial.
Lancet Oncol;
23(6): 818-828, 2022 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35654052
6.
A phase 3, randomized study of ofatumumab combined with bendamustine in rituximab-refractory iNHL (COMPLEMENT A + B study).
Br J Haematol;
193(6): 1123-1133, 2021 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33973233
7.
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.
Lancet;
395(10232): 1278-1291, 2020 04 18.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32305093
8.
A five-year follow-up of untreated patients with chronic lymphocytic leukaemia treated with ofatumumab and chlorambucil: final analysis of the Complement 1 phase 3 trial.
Br J Haematol;
190(5): 736-740, 2020 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32236950
9.
Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1.
Haematologica;
105(10): 2440-2447, 2020 10 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33054084
10.
Safety and efficacy of self-administered romiplostim in patients with immune thrombocytopenia: Results of an integrated database of five clinical trials.
Am J Hematol;
95(6): 643-651, 2020 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32129511
11.
Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia.
Haematologica;
104(10): 2053-2060, 2019 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31097627
12.
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
N Engl J Med;
373(25): 2425-37, 2015 Dec 17.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26639149
13.
Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia.
Blood;
137(8): 1117-1120, 2021 02 25.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33027809
14.
Improving lymph node characterization in staging malignant lymphoma using first-order ADC texture analysis from whole-body diffusion-weighted MRI.
J Magn Reson Imaging;
48(4): 897-906, 2018 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29656584
15.
Ibrutinib Regimens in Older Patients with Untreated CLL.
N Engl J Med;
380(17): 1679-1681, 2019 04 25.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31018080
16.
A large observational study of patients with primary immune thrombocytopenia receiving romiplostim in European clinical practice.
Eur J Haematol;
98(2): 112-120, 2017 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27557853
17.
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
Lancet Oncol;
17(2): 200-211, 2016 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26655421
18.
Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial.
Lancet;
385(9980): 1873-83, 2015 May 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25882396
19.
Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia.
Ann Hematol;
95(7): 1077-87, 2016 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27130310
20.
A phase 2, multicenter study investigating ofatumumab and bendamustine combination in patients with untreated or relapsed CLL.
Am J Hematol;
91(9): 900-6, 2016 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27222473